Loading organizations...
Key people at Symptom.ly.
Symptom.ly provides a clinically-validated, web-based platform for tracking patient-entered health symptoms. It functions as a dashboard and communication portal, enabling primary care providers, researchers, and patients to monitor health data. The platform delivers real-time, actionable insights, exemplified by eAsthma Tracker's significant reduction in pediatric asthma hospital readmissions.
Co-founded by Derek Bereit and Dillon Lee, Symptom.ly stemmed from University of Utah research. This work, focused on patient-entered data for chronic disease, led to the company's formation and its 2014 Techstars accelerator graduation. Bereit, a finance and technology attorney, and Lee, from the university’s venture commercialization office, commercialized this technology.
Symptom.ly’s platform serves primary care providers, insurance payers, and patients, with a focus on chronic illness management. Its vision is to transform chronic care, improving patient outcomes and lowering costs through symptom data. It facilitates proactive, efficient health management via timely information.
Key people at Symptom.ly.
Symptom.ly is a clinically validated SaaS symptom-tracking platform designed for insurers, doctors, and patients to monitor symptoms and reduce the costs associated with chronic illness management.[1][2] It serves healthcare providers, insurers, and patients by providing real-time data visualization on symptom progression, enabling better decision-making and cost efficiencies in chronic care.[1][2] The company has achieved "Full Product" stage and demonstrates growth momentum through participation in accelerators like Sprint Mobile Health and Techstars, positioning it as an established player in digital health tools.[2]
Symptom.ly emerged as a startup based in Sandy, UT, USA, focusing on mobile health solutions for symptom tracking, though specific founding year, founders, or exact idea origin details are not detailed in available records.[1][2] It gained early traction as a participant in the Sprint Mobile Health Accelerator and Techstars programs, which likely provided pivotal validation and resources to develop its clinically validated platform.[2] These accelerator experiences mark key moments in scaling from concept to a full SaaS product ready for insurer and clinical adoption.[1][2]
Symptom.ly rides the telemedicine and remote patient monitoring wave, where AI-enhanced platforms enable continuous chronic illness oversight amid rising healthcare costs and demand for accessible care.[1][2][4][5] Timing aligns with post-pandemic telehealth expansion, AI-driven diagnostics, and predictive analytics trends that optimize patient routing and reduce unnecessary visits—market forces favoring tools like Symptom.ly for underserved chronic care segments such as diabetes or asthma.[4][5] It influences the ecosystem by contributing to data consolidation for better clinical decisions, supporting broader shifts toward personalized, cost-effective digital health via wearables and SaaS integration.[1][2][5]
Symptom.ly is poised to expand as AI and remote monitoring mature, potentially integrating with wearables for predictive chronic care analytics and deeper insurer partnerships.[1][2][5] Trends like personalized treatment via data insights and telemedicine scalability will shape its path, evolving its role from tracker to full decision-support platform amid growing ROI demands in healthcare.[4][5] As chronic illness burdens intensify, Symptom.ly's validated focus could amplify its ecosystem impact, reducing costs while enhancing patient outcomes—building directly on its accelerator-forged foundation for sustained growth.[1][2]
